Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ODAC Backs Random Sample Audits Of Progression Events

Executive Summary

FDA’s Oncologic Drugs Advisory Committee supports easing the current requirement for blinded, independent central review of 100% of patient scans in studies using progression-free survival as the primary endpoint. However, committee members say FDA needs the flexibility to require full case audits in certain circumstances, depending upon tumor type and study size.


Related Content

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset
Afinitor In Pancreatic Tumors: ODAC Sees Consistent Efficacy, But Favors Limits On Use


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts